If federal agents raided your clinic, your pharmacy, or your warehouse, or you opened a warning letter or a grand jury subpoena tied to peptides, a criminal case is already in motion. These investigations do not begin with the knock at the door.
If federal agents raided your clinic, your pharmacy, or your warehouse, or you opened a warning letter or a grand jury subpoena tied to peptides, a criminal case is already in motion. These investigations do not begin with the knock at the door. They begin months earlier, quietly, with shipping records, payment processor data, and your own marketing.
The peptide business grew up in a gap in the law. For years the rules were unclear, the FDA tolerated a lot, and an entire industry built itself around research use only labels and compounded GLP-1 drugs. The government has now decided to close that gap, and it is doing it with criminal charges instead of warning letters.
What is at risk is not a fine and a corrective action plan. Prosecutors in these cases pursue prison time, forfeiture of the money and property tied to the business, and the loss of every license and registration the operation depends on. Money laundering theories can pull in partners, investors, and accountants who never touched a vial.
Why now? In 2025 the FDA took semaglutide and tirzepatide off the drug shortage list. That ended the legal cover that let compounding pharmacies make GLP-1 drugs at scale. At the same time, more than a dozen research peptides like BPC-157 had already been pushed into a restricted category that bars pharmacies from compounding them for people. The safe harbor disappeared, and the businesses that kept going became targets. The Amino Asylum raid and the Peptide Sciences shutdown were the first visible moves in a much larger effort.
If you own, run, prescribe for, market, or supply a peptide or GLP-1 operation in any form, the exposure is real and it is happening now.
Peptide cases rarely start with the FBI. They usually start with the FDA.
The pattern is consistent. An FDA inspection of a pharmacy or warehouse produces a Form 483 list of observations. That becomes a warning letter. The warning letter gets referred to the FDA Office of Criminal Investigations. From there it moves to HHS-OIG and the Justice Department Consumer Protection Branch. By the time a grand jury is involved, the government already has years of shipping records, payment data, advertising history, and customer messages.
Other cases begin with the product itself. Customs and federal investigators track imports, and they know where the supply is coming from. Chinese peptide imports to the United States doubled to $328 million in 2025. Online vendors are watched, ordered offline, and in some cases prosecuted.
The marketing is almost always the strongest evidence against you. Instagram posts, TikTok ads, podcast clips, influencer discount codes, and website copy promoting peptides for weight loss or muscle growth become the proof of intent. The research use only disclaimer does not help when the marketing and the customers tell a different story.
The agencies in these cases work together: the FDA, the DOJ, the DEA, HHS-OIG, and more than forty state attorneys general who have asked the federal government to coordinate a crackdown.
A single peptide case can carry several stacked charges. Knowing which ones the government is building is the first step in fighting them.
Distribution of unapproved drugs under 21 U.S.C. §§ 331 and 333. Selling or distributing a drug the FDA never approved is a federal offense. It is a misdemeanor on a first offense and a felony, up to ten years per count, when the government alleges intent to defraud or mislead. This statute is the backbone of nearly every peptide prosecution.
Misbranding. If a label is false or misleading about what the product is really for, it is misbranded. Calling something a research chemical while selling it next to syringes and dosing guides has already supported enforcement actions.
Wire fraud under 18 U.S.C. § 1343. Every card transaction, every online order, every promotional email can become a separate wire fraud count, each carrying up to twenty years. A busy online vendor can face dozens of counts.
Conspiracy under 18 U.S.C. § 371. Conspiracy lets the government charge pharmacy owners, compounders, marketers, fulfillment operators, and medical directors together, even when one person's role looks small.
Money laundering under 18 U.S.C. §§ 1956 and 1957. Once the drug and fraud counts are in place, deposits and transfers between accounts and vendors become laundering counts, up to twenty years each. This is how prosecutors raise the pressure and push people toward cooperation.
Healthcare fraud under 18 U.S.C. § 1347 and Anti-Kickback violations. When peptide services are billed to insurance or Medicare, or when referral and affiliate arrangements involve payments for patients, these charges get added on top.
Behind the statutes, most of these cases come down to two questions, and the government has to win both.
Was the product an unapproved drug sold or distributed for human use? The label is not the answer. Prosecutors point to the marketing, the packaging, the dosing instructions, and the customers to show what the product was really for.
Did you act with criminal intent? The felony version of the drug statute and the fraud counts all require proof that you knew what you were doing was wrong. This is where many of these cases are won. An industry that operated in a gray area for a decade, on advice from consultants and lawyers, with no clear regulatory line, is not the same as a person who set out to break the law. Good faith is a defense, and the government has to overcome it.
For compounding pharmacies, there is a third battleground: whether the compounding was lawful under the §503A and §503B carve-outs. Whether the drug was made for a specific patient, whether the ingredient was on the FDA bulk substances list, whether a recognized quality standard existed, and whether a shortage exception applied are all factual fights, not slogans.
The consequences reach well past a courtroom.
On the criminal side, exposure depends on the counts. FDCA felony counts can carry up to ten years each. Wire fraud and money laundering counts can carry up to twenty years each. Sentences are driven by the Guidelines, which turn heavily on the dollar volume the government attributes to the operation, and those numbers add up fast in a high-volume business.
Forfeiture lets the government take the money and property it claims is tied to the conduct, and accounts can be frozen while the case is pending. One earlier peptide prosecution ended with a company forced to forfeit $1.79 million for distributing unapproved peptides including BPC-157.
For licensed people, a pharmacy license, a DEA registration, or a medical license can be lost, and those proceedings often move faster than the criminal case. Losing a registration can be as damaging to a business as the criminal charge itself.
For non-citizens, certain convictions carry immigration consequences, including removal.
These cases are not defended by pretending the sales did not happen. They are defended by attacking intent, the statutes, and the way the government built the case.
Pre-indictment intervention. A Form 483, a warning letter, an FDA subpoena, or a visit from OCI or HHS-OIG means the case is in development but charges are not yet filed. Early counsel can control document production, narrow the government's theory, and in some cases resolve the matter civilly instead of criminally. This is the most valuable window in a peptide case.
Statutory defense. The §503A and §503B compounding rules are technical, and most peptide indictments contain at least one count that does not survive a careful statutory analysis. Where the facts support it, regulatory experts can testify about bulk substance eligibility, quality standards, and shortage exceptions.
Intent defense. The felony drug counts and the fraud counts all require intent. Reliance on lawyers and consultants, the disclaimer practices the whole industry used for years, and the absence of a clear legal line are all part of the intent record.
Attacking the marketing theory. The government leans on advertising to prove intent. The context of that marketing, who created it, and what was actually represented can be challenged.
Source and importation. In import cases, what you knew about the source, the chain of custody, and the actual contents of the product all matter, and the government's assumptions do not always hold.
Witness credibility. Former employees, competitors, and cooperators drive many of these cases. Their motives and inconsistencies are fair game.
Search and procedural challenges. Records seized through a defective warrant, or evidence gathered in violation of your rights, may be subject to suppression.
Parallel proceedings. FDA, DEA, state pharmacy and medical boards, and civil class actions can all run at the same time as the criminal case. They have to be coordinated, because a statement in one can be used in another.
Peptide cases reward early action more than almost any other kind, because so much happens before charges are filed.
The FDA usually shows its hand first, through an inspection or a warning letter. Treated as paperwork to handle alone, those notices harden into a criminal referral. Treated seriously, they can sometimes be contained, narrowed, or resolved before the case ever becomes criminal.
Once an indictment is filed, the office has committed publicly, the exposure has crystallized, and the conversation shifts to damage control. The chance to keep a case civil, or to keep charges off the table entirely, lives in the period before that happens.
There are also hard rules in this moment that protect you only if you follow them. Do not destroy, delete, or alter any records, because that creates obstruction charges that are often easier to prove than the underlying case. Do not contact suppliers, employees, or partners about the investigation, because that can become witness tampering. And do not talk to agents without a lawyer.
People who call AMC Defense Law in these cases are usually physicians, clinic and pharmacy owners, telehealth operators, and wellness entrepreneurs who built real businesses in an area the law never made clear, and who are now facing federal agents.
Aaron M. Cohen has more than thirty years of experience defending serious federal cases, including healthcare and white collar matters. The firm built its peptide defense work as this enforcement wave developed, and it understands how FDA OCI builds these cases, how the DOJ charges them, and where the theories break down.
The firm represents physicians, clinic operators, compounding pharmacies, telehealth companies, and wellness brands facing federal and state investigations nationwide.
If your clinic or pharmacy has been raided, served, or warned, or if you have learned you are under investigation over peptides, semaglutide, or compounding, the time to bring in counsel is now, while charges are still being decided.
These cases are most dangerous when they are left alone to grow, and most defensible when someone gets ahead of them.
To discuss your situation confidentially with Aaron M. Cohen, contact AMC Defense Law to arrange a consultation.
For peptide vendors, clinics, and telehealth platforms, marketing copy is the evidence federal prosecutors are using to convert FDCA violations into multi-count wire fraud indictments.
Selling peptides through a Florida clinic or med spa? The Peptide Sciences shutdown shows how fast FDA and DOJ cases are hardening, and what to do first.
Thinking compounded peptides are already back? The FDA set a July 2026 meeting, but providers and pharmacies still face real legal risk before any rule change.
RFK Jr. announced 14 peptides may return to legal compounding status. The FDA has not changed a single rule. Here is what that gap means for prescribers, clinics, and compounding pharmacies facing federal exposure right now.
Clinics raided, pharmacies shut down, criminal indictments filed. The peptide space is one of the most legally dangerous gray zones in American healthcare. RFK Jr.'s comments are not a legal shield.
Marketing GLP-1, peptide, and compounded therapeutic practices operates in a heavily regulated environment where business model design and advertising claims can trigger federal criminal investigation.